Added to YB: 2025-12-22
Pitch date: 2025-12-18
VKTX [bullish]
Viking Therapeutics, Inc.
+3.47%
current return
Author Info
Alpha Talon Investment Research is a Hong Kong–based private family office deploying only proprietary capital across biotech, value turnarounds, and catalyst-driven shorts, focused on intrinsic value, regulatory odds, and mispriced fundamentals. Sign up for the newsletter.
Company Info
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
Market Cap
$3.9B
Pitch Price
$34.01
Price Target
150.00 (+342%)
Dividend
N/A
EV/EBITDA
-11.53
P/E
-16.18
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Viking Therapeutics (NASDAQ: VKTX): The Last Independent Metabolic Challenger
VKTX: Late-stage metabolic biotech w/ dual GLP-1/GIP agonist VK2735 (injectable + oral) showing 14.7%/12.2% weight loss in Phase 2. $715M cash funds through 2027 Phase 3 trials. Oral formulation targets underserved population resistant to injectables. Patents extend to 2042-45. Base case $110 PT, bull case $150+ on M&A potential given scarcity of independent oral incretin assets.
Read full article (16 min)